We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.52B
AUM Growth
+$385M
Cap. Flow
+$52.4M
Cap. Flow %
0.62%
Top 10 Hldgs %
34.42%
Holding
155
New
17
Increased
44
Reduced
30
Closed
23

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$102M
2
CFN
CAREFUSION CORPORATION
CFN
+$68.7M
3
BMY icon
Bristol-Myers Squibb
BMY
+$60.2M
4
SHPG
Shire pic
SHPG
+$55.3M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$54M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$146M
2
AGN
Allergan Inc
AGN
+$113M
3
PRTA icon
Prothena Corp
PRTA
+$72.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$63M
5
XLRN
Acceleron Pharma
XLRN
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.04%
2 Miscellaneous 14.82%
3 Financials 0.08%
4 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCK icon
26
McKesson
MCK
$103B
$123M 1.44%
660,000
+81,000
+14% +$14.4M
ZBH icon
27
Zimmer Biomet
ZBH
$17.8B
$122M 1.44%
1,214,061
+476,375
+65% +$46.5M
PFE icon
28
Pfizer
PFE
$158B
$121M 1.42%
4,302,428
+443,734
+11% +$12.6M
HNT
29
DELISTED
HEALTH NET INC
HNT
$119M 1.4%
2,875,400
+315,400
+12% +$11.8M
AGN
30
DELISTED
Allergan plc
AGN
$119M 1.39%
532,000
+37,000
+7% +$7.66M
STJ
31
DELISTED
St Jude Medical
STJ
$115M 1.35%
1,663,600
+517,000
+45% +$33.5M
MOH icon
32
Molina Healthcare
MOH
$11.2B
$114M 1.34%
2,562,900
+309,900
+14% +$12.6M
TRNX
33
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$95.2M 1.12%
4,073,800
+2,598,700
+176% +$54M
REGN icon
34
Regeneron Pharmaceuticals
REGN
$81.7B
$92.3M 1.08%
326,600
-212,400
-39% -$63M
BMRN icon
35
BioMarin Pharmaceuticals
BMRN
$12.9B
$89.3M 1.05%
1,435,400
-57,600
-4% -$3.48M
SYK icon
36
Stryker
SYK
$108B
$83.9M 0.98%
994,600
+367,900
+59% +$30M
PODD icon
37
Insulet
PODD
$9.56B
$77.5M 0.91%
1,953,000
+19,500
+1% +$749K
ARWR icon
38
Arrowhead Research
ARWR
$11.4B
$70.9M 0.83%
4,957,800
+1,047,800
+27% +$13.7M
NBIX icon
39
Neurocrine Biosciences
NBIX
$16B
$69.4M 0.81%
4,675,700
-775,300
-14% -$10.9M
SPY icon
40
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
$68.5M 0.8%
350,000
-50,000
-13% -$9.51M
INFI
41
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$60.3M 0.71%
4,736,900
– –
AFFX
42
DELISTED
Affymetrix Inc
AFFX
$58.5M 0.69%
6,568,000
-125,000
-2% -$995K
LAB icon
43
Standard BioTools
LAB
$271M
$54.7M 0.64%
1,862,200
+415,000
+29% +$13.3M
JNJ icon
44
Johnson & Johnson
JNJ
$642B
$50.4M 0.59%
482,000
-115,000
-19% -$11.6M
VRTX icon
45
Vertex Pharmaceuticals
VRTX
$132B
$50M 0.59%
528,000
+368,000
+230% +$25.8M
ALXN
46
DELISTED
Alexion Pharmaceuticals
ALXN
$48.8M 0.57%
312,000
+45,000
+17% +$7.11M
OSUR icon
47
OraSure Technologies
OSUR
$232M
$46.3M 0.54%
5,372,000
– –
AGN
48
CALL
DELISTED
Allergan Inc
AGN
$42.3M 0.5%
250,000
+50,000
+25% +$7.78M
PTLA
49
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$39.7M 0.47%
1,361,600
+403,900
+42% +$9.78M
IBB icon
50
PUT
iShares Biotechnology ETF
IBB
$10.4B
$38.6M 0.45%
450,000
+150,000
+50% +$11.8M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2014 Portfolio in Review

As of Q2 2014, OrbiMed held 155 positions worth $8.52B, up 4.7% from $8.13B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2014 filing shows 17 new, 44 increased, 30 reduced and 23 closed positions. Its largest new stake was Alkermes: 433,300 shares worth $21.8M. The largest sale was Gilead Sciences, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Financials.

  • OrbiMed's largest Q2 2014 buy was Alkermes: 433,300 shares worth $21.8M.
  • OrbiMed added most to Ironwood Pharmaceuticals in Q2 2014, an estimated $102M increase.
  • OrbiMed's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $146M.
  • OrbiMed fully exited Prothena Corp in Q2 2014, selling an estimated $72.4M.
  • OrbiMed's ten largest holdings make up 34% of its $8.52B portfolio in Q2 2014.
  • OrbiMed opened 17 new positions and closed 23 in Q2 2014.
  • OrbiMed's portfolio value rose 4.7% quarter-over-quarter to $8.52B.

Based on OrbiMed's 13F filing for Q2 2014, filed 14 Aug 2014.